Seres receives Nasdaq bid-price deficiency notice; Q3 net loss $51M from cont. ops; SER-155 shows 77% BSI reduction

Seres Therapeutics, Inc.

Nasdaq notified Seres (MCRB) that bid price closed below $1.00 for 30 consecutive business days; must regain compliance by May 6, 2025.
Q3 2024 net loss from continuing ops $51M (vs $41M in Q3 2023); R&D exp $16.5M, G&A $12.7M.
SER-155 Phase 1b: 77% relative risk reduction in bloodstream infections, lower antibiotic use & febrile neutropenia vs placebo; Breakthrough Therapy requested.
VOWST sale closed Sep 2024 for ~$175M gross proceeds; expects $50M in Jan 2025 and $25M in Jul 2025; no debt outstanding.
Cash $66.8M as of Sep 30; expects to fund into Q4 2025 with existing cash and installment payments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.